REFERENCES
1. Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557-88.
2. Kelley RK, Bridgewater J, Gores GJ, Zhu AX. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72:353-63.
3. Mazzaferro V, Gorgen A, Roayaie S, Droz Dit Busset M, Sapisochin G. Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72:364-77.
4. Berardi G, Risi L, Muttillo EM, et al. Anatomic versus non-anatomic liver resection for intrahepatic cholangiocarcinoma: a systematic review and patient-level meta-analysis. Ann Surg Oncol. 2024;31:9170-82.
5. Kelley RK, Ueno M, Yoo C, et al.; KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1853-65.
6. Oh DY, He AR, Bouattour M, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9:694-704.
7. Tesini G, Ibrahim H, Rimassa L, Braconi C. Evolving precision: updates in targeted therapy for cholangiocarcinoma. Hepatology. 2025;Epub ahead of print.
8. Villard C, Habib M, Nordenvall C, Nilsson PJ, Jorns C, Sparrelid E. Conversion therapy in patients with colorectal liver metastases. Eur J Surg Oncol. 2021;47:2038-45.
9. Wang MD, Xu XJ, Wang KC, et al. Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: current status, challenges and opportunities. Cancer Sci. 2024;115:2159-69.
10. Xu H, Zhang H, Li B, Chen K, Wei Y. Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC Cancer. 2024;24:1008.
11. Adam R, Wicherts DA, de Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009;27:1829-35.
12. Perri G, Engstrand J, Wright RD, et al. The evolving concept of conversion surgery for upfront unresectable upper gastrointestinal and hepato-pancreato-biliary cancers: comprehensive review. BJS Open. 2025;9:zraf070.
13. Association for the Study of the Liver. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. J Hepatol. 2023;79:181-208.
14. Vogel A, Bridgewater J, Edeline J, et al.; ESMO Guidelines Committee. Electronic address: [email protected]. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:127-40.
15. Benson AB, D’Angelica MI, Abrams T, et al. NCCN Guidelines® insights: biliary tract cancers, version 2.2023. J Natl Compr Canc Netw. 2023;21:694-704.
16. Mehrabi A, Golriz M, Ramouz A, et al. Promising outcomes of modified ALPPS for staged hepatectomy in cholangiocarcinoma. Cancers. 2023;15:5613.
17. Conci S, Viganò L, Ercolani G, et al. Outcomes of vascular resection associated with curative intent hepatectomy for intrahepatic cholangiocarcinoma. Eur J Surg Oncol. 2020;46:1727-33.
18. Tsilimigras DI, Sahara K, Wu L, et al. Very early recurrence after liver resection for intrahepatic cholangiocarcinoma: considering alternative treatment approaches. JAMA Surg. 2020;155:823-31.
19. Choi WJ, Williams PJ, Claasen MPAW, et al. Systematic review and meta-analysis of prognostic factors for early recurrence in intrahepatic cholangiocarcinoma after curative-intent resection. Ann Surg Oncol. 2022;Epub ahead of print.
20. Moazzam Z, Alaimo L, Endo Y, et al. Combined tumor burden score and carbohydrate antigen 19-9 grading system to predict outcomes among patients with intrahepatic cholangiocarcinoma. J Am Coll Surg. 2023;236:804-13.
21. Nassar A, Tzedakis S, Sindayigaya R, et al. Factors of early recurrence after resection for intrahepatic cholangiocarcinoma. World J Surg. 2022;46:2459-67.
22. Schadde E, Grunhagen DJ, Verhoef C, Krzywon L, Metrakos P. Limitations in resectability of colorectal liver metastases 2020 - a systematic approach for clinicians and patients. Semin Cancer Biol. 2021;71:10-20.
23. Conci S, Ruzzenente A, Viganò L, et al. Patterns of distribution of hepatic nodules (single, satellites or multifocal) in intrahepatic cholangiocarcinoma: prognostic impact after surgery. Ann Surg Oncol. 2018;25:3719-27.
24. Zhang B, Wang XY, Yang LY, et al. Genetic predictors of postoperative recurrence in node-negative intrahepatic cholangiocarcinoma. Updates Surg. 2025;77:675-84.
25. Viganò L, Risi L, Ammirabile A. New perspectives in biology-driven treatment of cholangiocarcinoma: from oncological resectability to genetic breakthroughs and AI-powered imaging. Hepatobiliary Surg Nutr. 2025;14:703-8.
26. Cervantes A, Adam R, Roselló S, et al.; ESMO Guidelines Committee. Electronic address: [email protected]. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10-32.
27. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.
28. Wells GA, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The newcastle-ottawa scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. Available from: https://www.researchgate.net/publication/261773681_The_Newcastle-Ottawa_Scale_NOS_for_Assessing_the_Quality_of_Non-Randomized_Studies_in_Meta-Analysis. [Last accessed on 13 May 2026].
29. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-58.
30. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549.
31. Chen Y, Chen D, Wang Y, Han Y. Using freeman-tukey double arcsine transformation in meta-analysis of single proportions. Aesthetic Plast Surg. 2023;47:83-4.
32. Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.
33. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
34. Wei Y, Royston P. Reconstructing time-to-event data from published Kaplan-Meier curves. Stata J. 2017;17:786-802.
35. Burke DL, Ensor J, Riley RD. Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. Stat Med. 2017;36:855-75.
36. de Jong VMT, Moons KGM, Riley RD, et al. Individual participant data meta-analysis of intervention studies with time-to-event outcomes: a review of the methodology and an applied example. Res Synth Methods. 2020;11:148-68.
37. Royston P, Parmar MK. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med. 2011;30:2409-21.
38. Lueza B, Rotolo F, Bonastre J, Pignon JP, Michiels S. Erratum to: bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis. BMC Med Res Methodol. 2016;16:71.
39. Dong Y, Santol J, Podrascanin V, et al. Conversion to resection after neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel for borderline resectable CCA: a real-world exploratory analysis. Ann Surg Oncol. 2025;32:7215-27.
40. Nakamura I, Hatano E, Baba H, et al. Impact of conversion surgery after chemotherapy in patients with initially unresectable and recurrent biliary tract cancer. Ann Gastroenterol Surg. 2023;7:1009-20.
41. Alaimo L, Moazzam Z, Lima HA, et al. Impact of staging concordance and downstaging after neoadjuvant therapy on survival following resection of intrahepatic cholangiocarcinoma: a bayesian analysis. Ann Surg Oncol. 2023;30:4799-808.
42. Ayabe RI, Paez-Arango N, Estrella JS, et al. Neoadjuvant chemotherapy for high-risk intrahepatic cholangiocarcinoma - does pathologic response mean better outcomes? HPB. 2023;25:472-80.
43. Choi SH, Kang I, Lee SH, et al. Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma. Surgery. 2023;173:280-8.
44. Choi WJ, Ivanics T, Claasen MPAW, Gallinger S, Hansen B, Sapisochin G. Is it safe to administer neoadjuvant chemotherapy to patients undergoing hepatectomy for intrahepatic cholangiocarcinoma? ACS-NSQIP propensity-matched analysis. HPB. 2022;24:1535-42.
45. Garita E, Sarwar A, Tahir M, et al. Yttrium90-TARE with or without chemotherapy may improve survival in patients with locally advanced unresectable intrahepatic cholangiocarcinoma. Discov Oncol. 2025;16:1386.
46. Kato A, Shimizu H, Ohtsuka M, et al. Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery. Ann Surg Oncol. 2015;22:S1093-9.
47. Konstantinidis IT, Groot Koerkamp B, Do RK, et al. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer. 2016;122:758-65.
48. Kosaka H, Matsui K, Ikeura T, et al. Prognostic impact of combination therapy with gemcitabine and cisplatin plus S-1 and subsequent conversion surgery for initially unresectable upper biliary tract cancers. Surg Today. 2025;55:351-9.
49. Le Roy B, Gelli M, Pittau G, et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Br J Surg. 2018;105:839-47.
50. Maithel SK, Keilson JM, Cao HST, et al. NEO-GAP: a single-arm, phase II feasibility trial of neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel for resectable, high-risk intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2023;30:6558-66.
51. Mason MC, Massarweh NN, Tzeng CD, et al. Time to rethink upfront surgery for resectable intrahepatic cholangiocarcinoma? Implications from the neoadjuvant experience. Ann Surg Oncol. 2021;28:6725-35.
52. Murakami T, Matsuyama R, Yabushita Y, et al. Efficacy of conversion surgery for initially unresectable biliary tract cancer that has responded to down-staging chemotherapy. Cancers. 2025;17:873.
53. Nooijen LE, Franken LC, Belkouz A, et al. Efficacy and safety of gemcitabine plus cisplatin as potential preoperative chemotherapy in locally advanced intrahepatic, perihilar, and mid-cholangiocarcinoma: a retrospective cohort study. Am J Clin Oncol. 2021;44:526-32.
54. Riby D, Mazzotta AD, Bergeat D, et al. Downstaging with radioembolization or chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2020;27:3729-37.
55. Sutton TL, Billingsley KG, Walker BS, et al. Neoadjuvant chemotherapy is associated with improved survival in patients undergoing hepatic resection for intrahepatic cholangiocarcinoma. Am J Surg. 2021;221:1182-7.
56. Van Treeck BJ, Olave MC, Watkins RD, et al. Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinoma. HPB. 2024;26:938-48.
57. Wang Z, Jin Y, Guo Y, et al. Conversion therapy of intrahepatic cholangiocarcinoma is associated with improved prognosis and verified by a case of patient-derived organoid. Cancers. 2021;13:1179.
58. Wehrle CJ, Chang J, Woo K, et al. Neoadjuvant therapy reduces node positivity but does not confer survival benefit versus up-front resection for resectable intrahepatic cholangiocarcinoma: a propensity-matched analysis. J Surg Oncol. 2024;130:453-61.
59. Wu G, Chen X, Luo R, et al. Histopathologic grading of residual tumor predicts survival of intrahepatic cholangiocarcinoma patients treated with neoadjuvant therapy: major pathologic response and its clinical significance. Am J Surg Pathol. 2025;49:578-87.
60. Parente A, Kamarajah SK, Baia M, et al. Neoadjuvant chemotherapy for intrahepatic, perihilar, and distal cholangiocarcinoma: a national population-based comparative cohort study. J Gastrointest Surg. 2023;27:741-9.
61. Yadav S, Xie H, Bin-Riaz I, et al. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: a propensity score matched analysis. Eur J Surg Oncol. 2019;45:1432-8.
62. Lai Q, Parisse S, Ginanni Corradini S, et al. Evolution of transplant oncology indications: a single-institution experience over 40 years. Updates Surg. 2024;76:911-21.
63. Kim KD, Lee JE, Kim J, et al. Laparoscopic liver resection as a treatment option for intrahepatic cholangiocarcinoma. Updates Surg. 2024;76:869-78.
64. Huiskens J, Bolhuis K, Engelbrecht MR, et al.; Dutch Colorectal Cancer Group. Outcomes of resectability assessment of the dutch colorectal cancer group liver metastases expert panel. J Am Coll Surg. 2019;229:523-32.e2.
65. Serenari M, Ratti F, Hilal MA, et al. Liver hypertrophy techniques: a position paper from the Italian Group of Regenerative and Occlusive Worldwide-used techniques of hepatic Hypertrophy (I GROWtoH). Updates Surg. 2025;77:2155-71.
66. Farges O, Fuks D, Boleslawski E, et al. Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 study group. Ann Surg. 2011;254:824-29.
67. Sposito C, Maspero M, Cucchetti A, Mazzaferro V. A snapshot on current approaches to lymphadenectomy in liver resection for intrahepatic cholangiocarcinoma: results from an international survey. Updates Surg. 2024;76:1797-805.
68. Bismuth H, Adam R, Lévi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224:509-20.
69. Schartz DA, Porter M, Schartz E, et al. Transarterial Yttrium-90 radioembolization for unresectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Vasc Interv Radiol. 2022;33:679-86.
70. Savic LJ, Chapiro J, Geschwind JH. Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects. Hepatobiliary Surg Nutr. 2017;6:7-21.
71. Liu JJ, Zhou M, Yuan T, Huang ZY, Zhang ZY. Conversion treatment for advanced intrahepatic cholangiocarcinoma: opportunities and challenges. World J Gastroenterol. 2025;31:104901.
72. Nordlinger B, Sorbye H, Glimelius B, et al.; EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007-16.
73. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065-72.
74. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460-6.
